RayKnowChina Research Map
Shortlist0

ChangshaCentral South University (Xiangya)

Third Xiangya Hospital

中南大学湘雅三医院

Listed for 21 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Third Xiangya Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌18 papers led
  2. Hepatocellular carcinoma肝细胞癌41 papers led
  3. Stomach cancer胃癌17 papers led
  4. Retinoblastoma视网膜母细胞瘤1 paper led
  5. Chordoma脊索瘤1 paper led
  6. Osteosarcoma骨肉瘤24 papers led
  7. Neuroblastoma神经母细胞瘤2 papers led
  8. Multiple myeloma多发性骨髓瘤19 papers led
  9. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  10. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症6 papers led
  11. Haemophilia A血友病 A0 papers led
  12. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  13. Myasthenia gravis重症肌无力3 papers led
  14. Idiopathic pulmonary fibrosis特发性肺纤维化12 papers led
  15. Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
  16. Pompe disease庞贝病0 papers led
  17. Behçet disease白塞病1 paper led
  18. Alport syndromeAlport 综合征0 papers led
  19. IgA nephropathyIgA 肾病4 papers led
  20. Osteogenesis imperfecta成骨不全症0 papers led
  21. Leber hereditary optic neuropathyLeber 遗传性视神经病变0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 18 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
18
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 6620232024: 5520242025: 332025

5 hospitals in Changsha for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06788002

    Age 18 years to 70 years (registered criteria)

    Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyInduction / concurrent chemotherapyRecurrent / metastatic disease
Departments in papersENT / head & neck surgeryMedical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led18
  1. Immune archetypes TIME classification system for nasopharyngeal carcinoma: A new direction for precision immunotherapy.2025Biochimica et biophysica acta. Reviews on cancer
  2. BRD7 Inhibited Immune Escape in Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.2025International journal of biological sciencesFree full text
  3. Targeting ALG3/FOXD1/BNIP3 Axis Prevents Mitophagy and Gemcitabine Resistance of Nasopharyngeal Carcinoma.2025International journal of biological sciencesFree full text
  4. PLUNC inhibits invasion and metastasis in nasopharyngeal carcinoma by inhibiting NLRP3 inflammasome activation.2024Biochimica et biophysica acta. Molecular basis of disease
  5. Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2.2024Cell communication and signaling : CCSFree full text
  6. Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  7. APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1.2024International immunopharmacology
  8. TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance.2024International journal of biological sciencesFree full text
  9. MicroRNA-101-3p inhibits nasopharyngeal carcinoma cell proliferation and cisplatin resistance through ZIC5 down-regulation by targeting SOX2.2023Biological chemistry
  10. Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axis.2023Cell biology and toxicology
  11. circRNA_0067717 promotes paclitaxel resistance in nasopharyngeal carcinoma by acting as a scaffold for TRIM41 and p53.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  12. Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma.2023Cellular signalling
  13. The immune escape mechanism of nasopharyngeal carcinoma.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  14. LncRNA SNHG1 promotes nasopharyngeal carcinoma development via targeting miR-424-5p.2023Histology and histopathology
  15. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway.2022Journal of translational medicineFree full text
  16. Genetic profile identification and clinicopathologic characteristics analysis of the thyroid-like low-grade nasopharyngeal papillary adenocarcinoma.2022Pathology, research and practice
  17. Transcription factor STAT1 promotes the proliferation, migration and invasion of nasopharyngeal carcinoma cells by upregulating LINC01160.2021Future oncology (London, England)
  18. Reply: Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma: Methodological issues.2021Head & neck
Chinese-language papers (not in the count)2
  1. Analysis and projection of the disease burden of nasopharyngeal carcinoma in China based on the GBD database.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. HDAC6-mediated deacetylation of FLOT2 maintains stability and tumorigenic function of FLOT2 in nasopharyngeal carcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Intestinal Flora Sequencing for Nasopharyngeal CarcinomaCompletedNCT04094545Lead sponsorStart 2018-08
  2. LDRT and Chemoimmunotherapy in NPC With Liver MetastasisRecruitingNCT06788002Study sitePhase 2Start 2025-01
More papers found outside PubMed (not counted)4
  1. Bionic nanobombs target nasopharyngeal carcinoma to enhance the efficacy of chemoradiotherapy by destroying DNA damage repair systems2025Open Research (University of Surrey)article
  2. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figsharedataset
  3. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023Venue not listedother
  4. The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 41 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
41
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 7720222023: 101020232024: 8820242025: 992025

6 hospitals in Changsha for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led41
  1. Detection of macrotrabecular-massive hepatocellular carcinoma based on viscoelastic characteristics obtained by multifrequency magnetic-resonance elastography.2026European radiologyFree full text
  2. MicroRNA-6069 ASO inhibits the growth of hepatocellular carcinoma by PLEKHO1.2025Biochimica et biophysica acta. General subjects
  3. Analysis of influencing factors for achieving textbook outcome after laparoscopic right posterior sectionectomy of hepatocellular carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. The role of solute carrier family 16 member 3 protein in hepatocellular carcinoma and sorafenib resistance.2025International journal of biological macromolecules
  5. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  6. Liver B Cells Promotes MASLD Progression via the Apelin/APLNR System.2025International journal of medical sciencesFree full text
  7. Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  8. Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.2025Journal of experimental & clinical cancer research : CRFree full text
  9. Gene expression profile of anoikis reveals new subtypes of liver cancer and discovery of therapeutic targets and biomarkers.2025Scientific reportsFree full text
  10. Exploration of safety indicators for radiotherapy in hepatocellular carcinoma: A real-world study.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  11. Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma.2024AgingFree full text
  12. SEH1L siliencing induces ferroptosis and suppresses hepatocellular carcinoma progression via ATF3/HMOX1/GPX4 axis.2024Apoptosis : an international journal on programmed cell deathFree full text
  13. Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma.2024Biochimica et biophysica acta. Reviews on cancer
  14. ZMAT2 condensates regulate the alternative splicing of TRIM28 to reduce cellular ROS accumulation, thereby promoting the proliferation of HCC cells.2024Cell communication and signaling : CCSFree full text
  15. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.2024Current medicinal chemistry
  16. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.2024Hepatology international
  17. Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic 2024Journal of gastroenterology and hepatology
  18. Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma.2024Pathology, research and practice
  19. ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis.2023BMC medical genomicsFree full text
  20. Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma.2023Biochemical genetics
  21. PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer.2023European journal of medical researchFree full text
  22. A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort.2023Frontiers in endocrinologyFree full text
  23. The impact of liver fibrosis on the progression of hepatocellular carcinoma via a hypoxia-immune-integrated prognostic model.2023International immunopharmacology
  24. Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma.2023Journal of nanobiotechnologyFree full text
  25. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.2023PeerJFree full text
  26. CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma.2023Radiology
  27. A novel approach for the analysis of single-cell RNA sequencing identifies TMEM14B as a novel poor prognostic marker in hepatocellular carcinoma.2023Scientific reportsFree full text
  28. Anoikis-related signature in liver hepatocellular carcinoma defines the YBX1/SPP1 axis by machine learning strategies and valid experiments.2023The journal of gene medicine
  29. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  30. CircCBFB is a mediator of hepatocellular carcinoma cell autophagy and proliferation through miR-424-5p/ATG14 axis.2022Immunologic research
  31. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.2022International journal of biological sciencesFree full text
  32. SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis.2022Journal of experimental & clinical cancer research : CRFree full text
  33. Circular RNA circ_GLIS2 suppresses hepatocellular carcinoma growth and metastasis.2022Liver international : official journal of the International Association for the Study of the Liver
  34. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma.2022Oncogene
  35. Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model.2022World journal of surgical oncologyFree full text
  36. TIGIT/PVR and LncRNA ANRIL dual-targetable PAMAM polymeric nanoparticles efficiently inhibited the hepatoma carcinoma by combination of immunotherapy and gene therapy.2021Journal of drug targeting
  37. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis.2021Liver international : official journal of the International Association for the Study of the Liver
  38. Bcl-2 Associated Athanogene 2 (BAG2) is Associated With Progression and Prognosis of Hepatocellular Carcinoma: A Bioinformatics-Based Analysis.2021Pathology oncology research : PORFree full text
  39. Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma.2021Radiology
  40. Enhanced Chemodynamic Therapy and Chemotherapy via Delivery of a Dual Threat ArtePt and Iodo-Click Reaction Mediated Glutathione Consumption.2021Small methods
  41. Crosstalk between lncRNA DANCR and miR-125b-5p in HCC cell progression.2021Tumori
Chinese-language papers (not in the count)5
  1. SPP2 plays a role in the tumorigenesis of hepatocellular carcinoma: A bioinformatic based analysis.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Construction of web-based prediction nomogram models for cancer-specific survival in patients at stage IV of hepatocellular carcinoma depending on SEER database.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesRCTFree full text
  3. Effect of miRNA-200b on the proliferation of liver cancer cells via targeting SMYD2/p53 signaling pathway.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  4. Influence of different region of interest sizes on CT-based radiomics model for microvascular invasion prediction in hepatocellular carcinoma.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesRCTFree full text
  5. [MicroRNA-424 inhibits autophagy and proliferation of hepatocellular carcinoma cells by targeting ATG14].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status14
  1. Clinical Trial of Radiotherapy in Treating Primary Hepatocellular CarcinomaStatus unknownNCT03614546Lead sponsorN/AStart 2018-10
  2. TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.Status unknownNCT04417764Lead (inferred)Phase 1Start 2019-06
  3. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  4. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Study sitePhase 2Start 2022-04
  5. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Study sitePhase 2Start 2022-12
  6. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  7. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  8. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  9. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  10. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  11. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  12. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01
  13. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownNCT03313596Study sitePhase 3Start 2013-03
  14. A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical ResectionTerminatedNCT01402908Study sitePhase 3Start 2011-08

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
17
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 5520232024: 0020242025: 882025

4 hospitals in Changsha for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologyENT / head & neck surgeryPediatrics
Papers it led17
  1. Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.2025Biochimica et biophysica acta. Reviews on cancer
  2. AKR1B1 Inhibits Ferroptosis and Promotes Gastric Cancer Progression via Interacting With STAT3 to Activate SLC7A11.2025Cell biology international
  3. Circular RNA TFRC/SCD1 mRNA interaction regulates ferroptosis and metastasis in gastric cancer.2025Cell death & diseaseFree full text
  4. Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.2025Clinical nuclear medicine
  5. Metabolic reprogramming in Helicobacter pylori infection: from mechanisms to therapeutics.2025Frontiers in cellular and infection microbiologyFree full text
  6. TRAF1 promotes the progression of Helicobacter pylori-associated gastric cancer through EGFR/STAT/OAS signalling.2025Life sciences
  7. VacA promotes pyroptosis via TNFAIP3/TRAF1 signaling to induce onset of atrophic gastritis.2025Microbiological research
  8. The expression signature, prognostic significance and immune cell infiltration of the OAS gene family in gastric cancer.2025Scientific reportsFree full text
  9. Construction of a lipid metabolism-related and immune-associated prognostic score for gastric cancer.2023BMC medical genomicsFree full text
  10. LHPP promotes the intracellular reactive oxygen species accumulation and sensitivity of gastric cancer to cisplatin via JNK and p38 MAPK pathways.2023Histology and histopathology
  11. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.2023PeerJFree full text
  12. Comprehensive analysis of COMMD10 as a novel prognostic biomarker for gastric cancer.2023PeerJFree full text
  13. Clinicopathological and prognostic significance of LKB1 expression in gastric cancer: a systematic review and meta-analysis.2023Scientific reportsFree full text
  14. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.2022BMJ openFree full text
  15. A deep learning method to assist with chronic atrophic gastritis diagnosis using white light images.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  16. The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019.2022Scientific reportsFree full text
  17. The impact of robotic technology on the learning curve for robot-assisted gastrectomy in the initial clinical application stage.2022Surgical endoscopy
Chinese-language papers (not in the count)3
  1. Clinical characteristics of non-HPV infection-associated gastric-type endocervical adenocarcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Comparison of the learning curve of robot-assisted and laparoscopic-assisted gastrectomy.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Risk factors for complications of therapeutic endoscopy for upper gastrointestinal subepithelial lesions.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Domestic Surgical Robot Clinical StudyStatus unknownNCT02752698Lead sponsorN/AStart 2015-01
  2. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap MethodRecruitingNCT05450835Study siteN/AStart 2022-09
  3. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Changsha for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Changsha for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 24 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
24
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 3320232024: 111120242025: 552025

14 hospitals in Changsha for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led24
  1. Development of a prognostic model for osteosarcoma based on macrophage polarization-related genes using machine learning: implications for personalized therapy.2025Clinical and experimental medicine
  2. Single-cell analysis links DCUN1D5 to immune remodeling and cisplatin resistance in recurrent osteosarcoma.2025Communications biology
  3. m6A methylation modification: Potential pathways to suppress osteosarcoma metastasis.2025International immunopharmacology
  4. Biopolymer-based bone scaffold for controlled Pt (IV) prodrug release and synergistic photothermal-chemotherapy and immunotherapy in osteosarcoma.2025Journal of nanobiotechnology
  5. Decoding the role of SLC25A5 in osteosarcoma drug resistance and CD8+ T cell exhaustion: The therapeutic potential of phyllanthin.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Single-Atom Cu Nanozyme-Loaded Bone Scaffolds for Ferroptosis-Synergized Mild Photothermal Therapy in Osteosarcoma Treatment.2024Advanced healthcare materials
  7. The Targeted Therapies for Osteosarcoma via Six Major Pathways.2024Current molecular pharmacology
  8. RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis.2024Environmental toxicology
  9. Identification of an ADME-related gene for forecasting the prognosis and responding to immunotherapy in sarcomas.2024European journal of medical research
  10. Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma.2024Frontiers in immunology
  11. METTL16 promotes osteosarcoma progression by downregulating VPS33B in an m6 A-dependent manner.2024Journal of cellular physiology
  12. M2 macrophage exosome-derived Apoc1 promotes ferroptosis resistance in osteosarcoma by inhibiting ACSF2 deubiquitination.2024Molecular carcinogenesis
  13. Bruceantinol targeting STAT3 exerts promising antitumor effects in in vitro and in vivo osteosarcoma models.2024Molecular carcinogenesis
  14. Disulfidptosis-related PABPC3 promotes tumor progression and inhibits immune activity in osteosarcoma.2024The journal of gene medicine
  15. Diverse cell death patterns-related signature for predicting prognosis and drug sensitivity of osteosarcoma patients.2024The journal of gene medicine
  16. Antigen processing and presentation-related signature-derived BNIP3 is a novel oncogene and immunotherapy determinant in osteosarcoma based on machine learning and in vitro validation.2024The journal of gene medicine
  17. Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma.2023Frontiers in immunology
  18. Prognosis-related VDAC1 regulates the proliferation and apoptosis of osteosarcoma cells via the MAPK signaling pathway.2023Genomics
  19. Exosomal miR-181a-5p derived from SAOS-2 cells promotes macrophages M2 polarization by targeting RORA.2023The Kaohsiung journal of medical sciences
  20. RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma.2022Journal of translational medicine
  21. A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects.2021ACS applied materials & interfaces
  22. Effect of the Notch1-mediated PI3K-Akt-mTOR pathway in human osteosarcoma.2021Aging
  23. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.2021Frontiers in immunology
  24. LncRNA-ROR/microRNA-185-3p/YAP1 axis exerts function in biological characteristics of osteosarcoma cells.2021Genomics
Chinese-language papers (not in the count)1
  1. Prognositic value of anoikis and tumor immune microenvironment-related gene in the treatment of osteosarcoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Earlier papers (2016–2020)14
  1. WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m6A-dependent manner.2020Cell death & disease
  2. miR-485-5p/HSP90 axis blocks Akt1 phosphorylation to suppress osteosarcoma cell proliferation and migration via PI3K/AKT pathway.2020Journal of physiology and biochemistry
  3. LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis.2020Molecular medicine (Cambridge, Mass.)
  4. High SENP3 Expression Promotes Cell Migration, Invasion, and Proliferation by Modulating DNA Methylation of E-Cadherin in Osteosarcoma.2020Technology in cancer research & treatment
  5. Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway.2019Journal of cellular and molecular medicine
  6. Interleukin-1β/nuclear factor-κB signaling promotes osteosarcoma cell growth through the microRNA-181b/phosphatase and tensin homolog axis.2019Journal of cellular biochemistry
  7. miR-194 Suppresses Proliferation and Migration and Promotes Apoptosis of Osteosarcoma Cells by Targeting CDH2.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  8. miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT/MMPs pathway.2017Biochemical and biophysical research communications
  9. IL-1β-induced NF-κB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  10. Primary osteosarcoma of frontal bone: A case report and review of literature.2017Medicine
  11. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.2017Oncotarget
  12. The tumor suppressive role of RASSF1A in osteosarcoma through the Wnt signaling pathway.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  13. [MicroRNA-150 inhibits osteosarcoma cell proliferation by targeting RUNX2 gene].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  14. [miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

8 hospitals in Changsha for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 19 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 7720232024: 4420242025: 552025

4 hospitals in Changsha for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsRelapse & resistanceCAR-T & cell therapy
Papers it led19
  1. Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple Myeloma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.2025Cancer immunology, immunotherapy : CIIFree full text
  3. MIR4726EccDNA drives bortezomib resistance in multiple myeloma by enhancing MIR4726-5p/NXF1/NKIRAS2 axis dependent autophagy.2025Cell communication and signaling : CCSFree full text
  4. Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes.2025Hematology (Amsterdam, Netherlands)
  5. Exosomal tRF-1003 induces angiogenesis via regulating the HIF1α/VEGF signaling in multiple myeloma.2025International immunopharmacology
  6. Multiple myeloma exosomal miRNAs suppress cGAS-STING antiviral immunity.2024Biochimica et biophysica acta. Molecular basis of disease
  7. Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.2024Current treatment options in oncology
  8. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.2024International immunopharmacology
  9. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.2024Journal of translational medicineFree full text
  10. The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib.2023Chemico-biological interactions
  11. Exosomal miR-21-5p derived from multiple myeloma cells promote renal epithelial-mesenchymal transition through targeting TGF-β/SMAD7 signalling pathway.2023Clinical and experimental pharmacology & physiology
  12. Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.2023European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  13. CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma.2023International journal of pharmaceutics
  14. Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?2023Journal of clinical nursing
  15. IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma.2023Scientific reportsFree full text
  16. The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  17. Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.2021Annals of hematologyFree full text
  18. tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma.2021BMC bioinformaticsFree full text
  19. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.2021International journal of medical sciencesFree full text
Chinese-language papers (not in the count)4
  1. Clinical significance of CD45 and CD200 expression in newly diagnosed multiple myeloma patients.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Construction of a treatment response prediction model for multiple myeloma based on multi-omics and machine learning.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Diagnosis and treatment of multiple myeloma in Hunan Province.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  4. Research progress in proteasome inhibitor resistance to multiple myeloma.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  3. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  4. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  5. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  6. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  7. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Study sitePhase 1Start 2019-12
  8. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  9. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

4 hospitals in Changsha for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildrenAntibody & targeted drugs

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 6 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.5%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 0020242025: 222025

4 hospitals in Changsha for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment regimensEBV & infection triggersChildren
Departments in papersPediatricsSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Changsha for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

5 hospitals in Changsha for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

4 hospitals in Changsha for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStandard immunotherapyBiologic & complement drugsAntibodies & diagnosis
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 12 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.2%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 4420232024: 2220242025: 222025

7 hospitals in Changsha for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led12
  1. A Rare TERT Mutation Associated with Idiopathic Pulmonary Fibrosis and COPD in a Chinese Family.2025Balkan medical journal
  2. Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages.2025International immunopharmacology
  3. Identification of key mitochondria-related genes and their potential crosstalk role with immune pattern in Idiopathic pulmonary fibrosis.2024Gene
  4. Succinate promotes pulmonary fibrosis through GPR91 and predicts death in idiopathic pulmonary fibrosis.2024Scientific reports
  5. Identification of the shared genes and immune signatures between systemic lupus erythematosus and idiopathic pulmonary fibrosis.2023Hereditas
  6. Establishment and application of the BRP prognosis model for idiopathic pulmonary fibrosis.2023Journal of translational medicine
  7. Ectopic and visceral fat deposition in aging, obesity, and idiopathic pulmonary fibrosis: an interconnected role.2023Lipids in health and disease
  8. S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function.2023Pulmonary pharmacology & therapeutics
  9. The Combined Model of CX3CR1-Related Immune Infiltration Genes to Evaluate the Prognosis of Idiopathic Pulmonary Fibrosis.2022Frontiers in immunology
  10. Retrospective analysis of skin photosensitivity induced by pirfenidone.2022Journal of clinical pharmacy and therapeutics
  11. The networks of m6A-SARS-CoV-2 related genes and immune infiltration patterns in idiopathic pulmonary fibrosis.2021Aging
  12. Investigation of a Hypoxia-Immune-Related Microenvironment Gene Signature and Prediction Model for Idiopathic Pulmonary Fibrosis.2021Frontiers in immunology
All its trials on ClinicalTrials.gov, any status3
  1. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  2. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08
  3. Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy AdultsCompletedNCT03619616Study sitePhase 1Start 2018-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

4 hospitals in Changsha for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changsha for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinical characteristics and GAA gene mutation in children with glycogen storage disease type II: an analysis of 3 cases].2017Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Changsha for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Changsha for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 0020242025: 002025

7 hospitals in Changsha for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrologyGastroenterology / hepatologyClinical trials / research unit
Papers it led4
  1. Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample Mendelian randomization study.2023European journal of medical research
  2. Prognostic value of low-density lipoprotein cholesterol in IgA nephropathy and establishment of nomogram model.2023Frontiers in endocrinology
  3. Iron metabolism and chronic inflammation in IgA nephropathy.2023Renal failure
  4. A Mendelian randomization study to assess the genetic liability of type 1 diabetes mellitus for IgA nephropathy.2022Frontiers in endocrinology
Earlier papers (2016–2020)2
  1. CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?2017Current gene therapy
  2. Identification of a novel collagen type IV alpha-4 (COL4A4) mutation in a Chinese family with autosomal dominant Alport syndrome using exome sequencing.2016The Indian journal of medical research
All its trials on ClinicalTrials.gov, any status5
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  4. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  5. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Changsha for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. COL1A2 p.Gly1066Val variant identified in a Han Chinese family with osteogenesis imperfecta type I.2019Molecular genetics & genomic medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led no English-language PubMed papers on Leber hereditary optic neuropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changsha for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Identification of an ND4 Mutation in Leber Hereditary Optic Neuropathy.2017Optometry and vision science : official publication of the American Academy of Optometry

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中南大学湘雅三医院

Third Xiangya Hospital

长沙

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Third Xiangya Hospital of Central South University; Central South University Third Xiangya Hospital; Transplantation Center of the Third Xiangya Hospital; Third XiangYa Hospital; 中南大学湘雅三医院-门急诊楼

Suggest a correctionDownload the data